JAK1 inhibitors for the treatment of atopic dermatitis: a focus on pharmacokinetic considerations

医学 特应性皮炎 托法替尼 社会心理的 鲁索利替尼 安全概况 药代动力学 临床试验 杜皮鲁玛 生活质量(医疗保健) 药理学 皮肤病科 不利影响 内科学 精神科 护理部 类风湿性关节炎 骨髓 骨髓纤维化
作者
Hannah Kopelman,Christina Kontzias,Christopher Alihosseni,Steven R. Feldman
出处
期刊:Expert Opinion on Drug Metabolism & Toxicology [Taylor & Francis]
卷期号:19 (8): 537-542 被引量:1
标识
DOI:10.1080/17425255.2023.2256227
摘要

ABSTRACTIntroduction Atopic dermatitis (AD) is associated with reduced quality of life, depression, and anxiety, making efficacious and safe treatments a priority. We will focus on the safety, efficacy, and pharmacokinetics of JAK1 inhibitors used in the treatment of AD.Areas Covered In this review, the pharmacodynamics, pharmacokinetics, safety, and efficacy of JAK1 inhibitors for the treatment of atopic dermatitis are discussed. The data was obtained by searching ClinicalTrials.gov, PubMed, and Google Scholar. Articles between January 2012 and March 2023 were considered for inclusion.Expert Opinion Given the rare, but serious black box warnings with JAK inhibitors, patients and providers may be weary of initiating treatment. In these instances, clinicians may weigh the risks and benefits of treatment with this class. Risk is relative, and while there are risks to treating AD with JAK inhibitors, there are also risks to untreated or undertreated AD, including infection and impairments in mental, physical, and psychosocial function. While JAK1 inhibitors appear to be safe, they were only recently approved for AD in January 2022, and more long-term safety data is needed. We expect to see additional FDA approval of these drugs, new formulations, and more safety and efficacy data in the future.KEYWORDS: AtopicdermatitisJAKpharmacodynamicspharmacokineticssafetyefficacy Article highlights JAK inhibitors are small molecules that bind to JAK receptors and block the downstream signaling from cytokines implicated in atopic dermatitis (AD), specifically IL-4 and IL-13.There are two classes of JAK inhibitors. The first generation – baricitinib, delgocitinib, tofacitinib, and ruxolitinib – inhibit multiple JAK isoforms. The second generation – abrocitinib and uadacitinib – are more selective, targeting primarily only one JAK isoform and inhibiting a smaller range of cytokines.JAK inhibitors were efficacious for AD in phase II and III clinical trials. In particular, upadacitinib was more efficacious than dupilumab in a head-to-head trial.As a class, the JAK inhibitors have similar safety profiles with the most frequent adverse events including nasopharyngitis and upper respiratory infections.Given the rare, but serious black box warnings for an increased risk of serious infections, mortality, malignancy, major adverse cardiovascular events, and thrombosis with JAK inhibitors, conversations surrounding using JAK inhibitors should involve risk stratification and shared decision-making between patients and their doctors.Declaration of interestS Feldman has received research, speaking and/or consulting support from Eli Lilly and Company, GaxoSmithKline/Stiefel, AbbVie, Janssen, Alovtech, vTv Therapeutics, Bristol-Myers Squibb, Samsung, Pfizer, Boehringer Ingelheim, Amgen, Dermavant, Arcutis, Novartis, Novan, UCB, Helsinn, Sun Pharma, Almirall, Galderma, Leo Pharma, Mylan, Celgene, Ortho Dermatology, Menlo, Merck & Co, Qurient, Forte, Arena, Biocon, Accordant, Argenx, Sanofi, Regeneron, the National Biological Corporation, Caremark, Teladoc, Ono, Micreos, Eurofins, Informa, UpToDate and the National Psoriasis Foundation. He is founder and part owner of Causa Research and holds stock in Sensal Health. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.Reviewer disclosuresOne reviewer has served on the advisory board of or as a consultant for; Regeneron, Sanofi Genzyme, AbbVie, Pfizer, Janssen-Cilag, LEO Pharma, Novartis, Eli-Lilly, Teva, L'Oreal, Pierre Fabre, Cantabria Labs, Organon, Viatris, Evelo Biosciences and Amgen. The remaining reviewers have no other relevant financial relationships or otherwise to disclose.Additional informationFundingThis paper was not funded.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
小小鱼完成签到 ,获得积分10
2秒前
2秒前
甜美砖家完成签到 ,获得积分10
4秒前
superspace完成签到,获得积分10
5秒前
nn发布了新的文献求助10
7秒前
求助完成签到,获得积分10
8秒前
9秒前
翁雁丝完成签到 ,获得积分10
16秒前
郭义敏完成签到,获得积分0
16秒前
gyf完成签到,获得积分10
19秒前
李保龙完成签到 ,获得积分10
20秒前
24秒前
LJJ完成签到 ,获得积分10
25秒前
量子星尘发布了新的文献求助10
28秒前
阿姨洗铁路完成签到 ,获得积分10
33秒前
抹不掉的记忆完成签到,获得积分10
35秒前
35秒前
余杭村王小虎完成签到,获得积分10
36秒前
韭黄完成签到,获得积分20
40秒前
jeffrey完成签到,获得积分10
40秒前
Rondab应助机灵枕头采纳,获得10
46秒前
佳无夜完成签到,获得积分10
51秒前
摆哥完成签到,获得积分10
55秒前
66完成签到,获得积分10
1分钟前
zlqq完成签到 ,获得积分10
1分钟前
Hardskills发布了新的文献求助10
1分钟前
1分钟前
之_ZH完成签到 ,获得积分10
1分钟前
gds2021完成签到 ,获得积分10
1分钟前
你好呀嘻嘻完成签到 ,获得积分10
1分钟前
梅特卡夫完成签到,获得积分10
1分钟前
熊雅完成签到,获得积分10
1分钟前
1分钟前
睡到自然醒完成签到 ,获得积分10
1分钟前
cis2014完成签到,获得积分10
1分钟前
独特的大有完成签到 ,获得积分10
1分钟前
量子星尘发布了新的文献求助10
1分钟前
1分钟前
xingyi完成签到,获得积分10
1分钟前
1分钟前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038112
求助须知:如何正确求助?哪些是违规求助? 3575788
关于积分的说明 11373801
捐赠科研通 3305604
什么是DOI,文献DOI怎么找? 1819255
邀请新用户注册赠送积分活动 892655
科研通“疑难数据库(出版商)”最低求助积分说明 815022